Style | Citing Format |
---|---|
MLA | Ghasempour G, et al.. "Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis." Current Medicinal Chemistry, vol. 31, no. 2, 2024, pp. 223-241. |
APA | Ghasempour G, Zamanigarmsiri F, Shaikhnia F, Soleimani AA, Fard SRH, Leila J, Teimuri S, Parvaz N, Mohammadi P, Najafi M (2024). Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Current Medicinal Chemistry, 31(2), 223-241. |
Chicago | Ghasempour G, Zamanigarmsiri F, Shaikhnia F, Soleimani AA, Fard SRH, Leila J, Teimuri S, Parvaz N, Mohammadi P, Najafi M. "Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis." Current Medicinal Chemistry 31, no. 2 (2024): 223-241. |
Harvard | Ghasempour G et al. (2024) 'Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis', Current Medicinal Chemistry, 31(2), pp. 223-241. |
Vancouver | Ghasempour G, Zamanigarmsiri F, Shaikhnia F, Soleimani AA, Fard SRH, Leila J, et al.. Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Current Medicinal Chemistry. 2024;31(2):223-241. |
BibTex | @article{ author = {Ghasempour G and Zamanigarmsiri F and Shaikhnia F and Soleimani AA and Fard SRH and Leila J and Teimuri S and Parvaz N and Mohammadi P and Najafi M}, title = {Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis}, journal = {Current Medicinal Chemistry}, volume = {31}, number = {2}, pages = {223-241}, year = {2024} } |
RIS | TY - JOUR AU - Ghasempour G AU - Zamanigarmsiri F AU - Shaikhnia F AU - Soleimani AA AU - Fard SRH AU - Leila J AU - Teimuri S AU - Parvaz N AU - Mohammadi P AU - Najafi M TI - Efficacy and Safety of Alirocumab and Evolocumab As Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis JO - Current Medicinal Chemistry VL - 31 IS - 2 SP - 223 EP - 241 PY - 2024 ER - |